Comparative Pharmacology
Head-to-head clinical analysis: FOSPHENYTOIN SODIUM versus TRILEPTAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOSPHENYTOIN SODIUM versus TRILEPTAL.
FOSPHENYTOIN SODIUM vs TRILEPTAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fosphenytoin is a water-soluble prodrug of phenytoin. It is converted to phenytoin, which stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting repetitive firing of action potentials and reducing seizure propagation.
Trileptal (oxcarbazepine) stabilizes neuronal membranes by blocking voltage-sensitive sodium channels, thereby inhibiting repetitive firing of action potentials. It also modulates high-voltage-activated calcium channels and increases potassium conductance.
Loading dose: 15-20 mg PE/kg IV at 100-150 mg PE/min; maintenance: 4-6 mg PE/kg/day IV divided every 8-12 hours.
Adults: 600 mg orally twice daily initially; titrate by 600 mg/day every week. Maintenance: 600-1200 mg twice daily.
None Documented
None Documented
The terminal elimination half-life of fosphenytoin is approximately 15 minutes (range 8-30 minutes) following IV administration; however, the half-life of the active metabolite phenytoin is 20-30 hours (dose-dependent) in adults, requiring careful monitoring for accumulation.
Parent oxcarbazepine: 1.3–2.3 hours; active metabolite MHD: 8–11 hours (monohydroxy derivative); clinically, the long MHD half-life supports twice-daily dosing.
Renal excretion of inactive metabolites (primarily fosphenytoin metabolites including phenytoin metabolites) accounts for approximately 80-90% of elimination; less than 5% excreted unchanged in urine; biliary/fecal excretion minimal.
Renal excretion is the primary route; 95% of the dose is excreted in urine (79% as MHD, 20% as MHD conjugates, <1% as unchanged oxcarbazepine), and 4% in feces.
Category D/X
Category C
Anticonvulsant
Anticonvulsant